J&J's Tecvayli recommended by NICE to treat relapsed and refractory multiple myeloma

22 Jul 2024
pmlive.com
Drug ApprovalClinical Result
J&J's Tecvayli recommended by NICE to treat relapsed and refractory multiple myeloma
Preview
Source: PMLiVE
The final draft guidance specifically applies to patients who have received at least three prior treatments, have progressed on their last treatment, and would otherwise be offered pomalidomide plus dexamethasone (pom-dex).
Approximately 5,900 people are diagnosed in the UK every year with multiple myeloma, an incurable blood cancer that affects a type of white blood cell called plasma cells.
The majority of patients will relapse and require subsequent therapy, with efficacy declining after each line of treatment.
Administered as a subcutaneous injection, Tecvayli is a bispecific antibody that works by redirecting T cells to multiple myeloma cells and helping to destroy them.
NICE’s decision was supported by clinical trial results showing that RRMM patients who received Tecvayli after three prior therapies had a median overall survival of 22 months and a median progression-free survival of 11 months.
Further data comparing Tecvayli to pom-dex demonstrated that J&J’s therapy reduces the risk of disease progression by 44% and the risk of death by 48%.
Amanda Cunnington, senior director of patient access, J&J Innovative Medicine UK, said: “Patients with multiple myeloma face several challenges – not least coping with recurrent relapses – and it’s vital that they can access novel treatment options that offer the potential for sustained remission and improved quality of life.”
Cunnington added that, while the draft guidance “meets the needs” of the majority of these patients, the company is “very concerned” that the proposed restriction applied by NICE removes this option from those who have been waiting for Tecvayli to become available on the NHS.
The recommendation comes just over two weeks after J&J received approvals from both the European Commission (EC) and the US Food and Drug Administration for its tuberculosis treatment, Sirturo (bedaquiline).
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.